NASDAQ : AKTS
Aktis Oncology, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 15.93 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 886.02M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 886.02M |
| Enterprise Value | 379.94M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 53.75M |
| Shares Outstanding | 55.62M |
| Shares Change (YoY) | +3,649.41% |
| Shares Change (QoQ) | +13.72% |
| Owned by Insiders (%) | 0.46% |
| Owned by Institutions (%) | 43.34% |
| Float | 28.59M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 88.07 |
| Forward PS | 113.42 |
| PB Ratio | 1.82 |
| P/TBV Ratio | 1.83 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 37.77 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 16.33 |
| Quick Ratio | 16.17 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -16.59% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | $127,342 |
| Profits Per Employee | -$925,823 |
| Employee Count | 79 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 20.57 |
| 200-Day Moving Average | 21.02 |
| Relative Strength Index (RSI) | 36.38 |
| Average Volume (20 Days) | 335,099 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 4.31M |
| Short Previous Month | 4.72M |
| Short % of Shares Out | 7.76% |
| Short % of Float | 15.09% |
| Short Ratio (days to cover) | 8.44 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 10.06M |
| Gross Profit | -68.22M |
| Operating Income | -87.18M |
| Pretax Income | -73.14M |
| Net Income | -73.14M |
| EBITDA | -84.36M |
| EBIT | -87.18M |
| Loss Per Share | -$2.77 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 517.32M |
| Total Debt | 11.24M |
| Net Cash | 506.08M |
| Net Cash Per Share | $9.10 |
| Equity (Book Value) | 484.84M |
| Book Value Per Share | 8.76 |
| Working Capital | 492.41M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -75.29M |
| Capital Expenditures | -9.27M |
| Depreciation & Amortization | 2.82M |
| Net Borrowing | n/a |
| Free Cash Flow | -84.57M |
| FCF Per Share | -$1.52 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | -866.63% |
| Pretax Margin | -727.04% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -3,649.41% |
| Shareholder Yield | n/a |
| Earnings Yield | -17.39% |
| FCF Yield | -9.54% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $35.88 |
| Price Target Difference | 125.24% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (3Y) | 13.56% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 8.98 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |